Isosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide-cyclic guanosine-3′, 5′-monophosphate disturbances

Thrombosis Research

Volumn 110, Issue 2-3, 2003, Pages 107-115

  Reis, Flávio ^a   Almeida, Luís ^a   Alcobia, Teresa ^a   Santos Dias, José D ^b   Lourenço, Margarida ^c   Palmeiro, Aida ^c   Ferrer Antunes, Carlos A ^c   Mesquita, José F ^b   Pontes, Fausto ^d   Teixeira, Frederico ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

cGMP; Cyclosporin A; Hypertension; Isosorbide 5 mononitrate; Nitric oxide; Nitric oxide synthase; Platelets; Thromboembolic complications

Indexed keywords

CALCIUM ION; COLLAGEN; CYCLIC GMP; CYCLOSPORIN A; ISOSORBIDE 5 NITRATE; MONOPRONT; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; THROMBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CALCIUM CELL LEVEL; CELL ACTIVITY; CONTROLLED STUDY; DIETARY INTAKE; DOSE RESPONSE; DRUG EFFECT; ELECTRON MICROSCOPY; ENZYME ACTIVITY; HYPERTENSION; MALE; NONHUMAN; ORANGE JUICE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

EID: 10744223826     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00311-6     Document Type: Article

References (39)

1. Borel J.F., Di Padova F., Mason J., Quesniaux V., Ryffel B., Wenger R. Pharmacology of cyclosporine (Sandimmune): I. Introduction. Pharmacol. Rev. 41:1989;239-242.
2. Kahan B.D. Cyclosporine. N. Engl. J. Med. 321:1989;1725-1738.
3. Vanrenterghem Y., Roels L., Lerut T., Gruwez L., Michielsen P., Gresele P.et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet. I:1985;999-1002.
4. Muraki T., Sasaki Y., Gidding J.C., Ishii H., Kaneko T., Yamamoto J. Antithrombotic effects of FK506 versus prothrombotic effect of cyclosporine in vivo. Transplantation. 60:1995;308-309.
5. Miller B.W., Hmiel S.P., Schnitzler M.A., Brennan D.C. Cyclosporine as cause of thrombotic microangiopathy after renal transplantation. Am. J. Kidney Dis. 29:1997;813-814.
6. Schachter M. Cyclosporine A and hypertension. J. Hypertens. 6:1988;511-516.
7. Sander M., Victor R.G. Hypertension after cardiac transplantation: pathophysiology and management. Curr. Opin. Nephrol. Hypertens. 4:1995;443-451.
8. Cartier R., Dagenais F., Hollmann C., Cambron H., Buluran J. Chronic exposure to cyclosporine affects endothelial and smooth muscle reactivity in the rat aorta. Ann. Thorac. Surg. 58:1994;789-794.
9. Stephan D., Billing A., Krieger J.P., Erima M., Fabre M., Hafner M.et al. Endothelium-dependent relaxation in the isolated rat kidney: impairment by cyclosporine A. J. Cardiovasc. Pharmacol. 26:1995;859-868.
10. Zoja C., Furci L., Ghilardi F., Zilio P., Benigni A., Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab. Invest. 55:1986;455-462.
11. Rego A., Vargas R., Wroblewska B., Foegh M.L., Ramwell P.W. Attenuation of vascular relaxation and cyclic GMP responses by cyclosporin A. J. Pharmacol. Exp. Ther. 252:1990;165-170.
12. Akita K., Dusting G.J., Hickey H. Suppression of nitric oxide production by cyclosporin A and FK506 in rat vascular smooth muscle cells. Clin. Exp. Pharmacol. 21:1994;231-233.
13. Marumo T., Nakaki T., Hishikawa K., Suzuki H., Kato R., Saruta T. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension. 25(Part 2):1995;764-768.
14. Vaziri N.D., Ni Z., Zhang Y.P., Ruzics E.P., Maleki P., Ding Y. Depressed renal and vascular nitric oxide synthase expression in cyclosporine-induced hypertension. Kidney Int. 54(2):1998;482-491.
15. O'Neil G.S., Chester A.H., Kushwaha S., Rose M., Tadjkarimi S., Yacoub M.H. Cyclosporin treatment does not impair the release of nitric oxide in human coronary arteries. Br. Heart J. 66:1991;212-216.
16. Stroes E.S., Luscher T.F., Groot F.G., Koomans H.A., Rabelink T.J. Cyclosporin A increases nitric oxide activity in vivo. Hypertension. 29:1997;570-575.
17. Hansen J.M., Johansen N.J., Mollerup H.M., Anderson N.F., Strandgaard S. Effects of nitric oxide blockade and cyclosporin A on cardiovascular and renal function in normal man. J. Hypertens. 17:1999;1707-1713.
18. Body S.C. Platelet activation and interactions with the microvasculature. J. Cardiovasc. Pharmacol. 27(Suppl. 1):1996;S13-S25.
19. White J.G. Platelets and atheriosclerosis. Eur. J. Clin. Invest. 24:1994;25-29.
20. Vanhoutte P.M. Platelets, endothelium and blood vessel wall. Experientia. 44:1988;105-108.
21. Radomski M.W., Palmer R.M.J., Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. Sci. U. S. A. 87:1990;5193-5197.
22. Bodzenta-Lukaszyk A., Gabryelewicz A., Lukaszyk A., Bielawiec M., Konturek J.W., Domschke W. Nitric oxide synthase inhibition and platelet function. Thromb. Res. 75(6):1994;667-672.
23. Berkels R., Stockklauser K., Rosen P., Rosen R. Current status of platelet NO synthase. Thromb. Res. 87(1):1997;51-55.
24. Reis F., Tavares P., Rito L.C., Teixeira H.M., Santos-Dias J.D., Ferrer-Antunes C.et al. Platelet activation is increased in cyclosporin A-induced hypertensive rats. J. Cardiovasc. Pharmacol. 36(1):2000;56-64.
25. Reis F., Tavares P., Fontes-Ribeiro C.A., Ferrer-Antunes C., Teixeira F. The peripheral serotonergic system and platelet aggregation in cyclosporin A-induced hypertensive rats. Thromb. Res. 96:1999;365-372.
26. Reis F., Tavares P., Teixeira F. The distribution of catecholamines between plasma and platelets in cyclosporin A-induced hypertensive rats. Pharmacol. Res. 41(2):2000;129-135.
27. Kim H.S., Kim D.H., Kang S.W., Choi K.H., Lee H.Y., Han D.S.et al. L-arginine restores suppressed acetylcholine-induced endothelium-dependent vascular relaxation in cyclosporin A-treated rats. Transplant. Proc. 28(3):1996;1372-1374.
28. Lee J., Kim S.W., Kook H., Kang D.G., Kim N.H., Choi K.C. Effects of L-arginine on cyclosporin-induced alterations of vascular NO/cGMP generation. Nephrol. Dial. Transplant. 14:1999;2634-2638.
29. Yang C.W., Kim Y.S., Kim J., Kim Y.O., Min S.Y., Choi E.J.et al. Oral supplementation of L-arginine prevents chronic cyclosporine nephrotoxicity in rats. Exp. Nephrol. 6:1998;50-56.
30. Santiago M., Reis F., Almeida L., Alcobia T., Dionísio J., Teixeira F. Impaired arterial and platelet nitric oxide and cyclic guanosine-3′,5′-monophosphate content in cyclosporin A-induced hypertensive rats. Fundam. Clin. Pharmacol. 17:2003;43-50.
31. Mehta J.L., Chen L.Y., Kone B.C., Mehta P., Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J. Lab. Clin. Med. 125:1995;370-377.
32. Chen L., Salafranca M.N., Mehta J.L. Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets. Am. J. Physiol. 273:1997;H1854-H1859.
33. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
34. Gunasekara N.S., Noble S. Isosorbide 5-mononitrate. A review of a sustained-release formulation (Indur®) in stable pectoris angina pectoris. Drugs. 57(2):1999;261-277.
35. Parker J.D., Parker J.O. Nitrate therapy for stable angina pectoris. Drug Ther. 338(8):1998;520-531.
36. Megson I.L. Nitric oxide donor drugs. Drug Fut. 25(7):2000;701-715.
37. Wirthumer-Hoche C., Silberhauer K., Sinzinger H. Effect on nitroglycerin and other organic nitrates on the in-vitro biosynthesis of arachidonic acid-metabolits in washed human platelets. Prostaglandins Leukot. Med. 15:1984;317-323.
38. Sinzinger H., Virgolini I., O'Grady J., Rauscha F., Fitsch P. Modification of platelet function by isosorbide dinitrate in patients with coronary artery disease. Thromb. Res. 65:1992;323-335.
39. Gilmer J.F., Moriarty L.M., McCafferty D.F., Clancy J.M. Synthesis, hydrolysis kinetics and anti-platelet effects of isosorbide mononitrate derivatives of aspirin. Eur. J. Pharm. Sci. 14(3):2001;221-227.